GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alumis Inc (NAS:ALMS) » Definitions » Total Liabilities

ALMS (Alumis) Total Liabilities : $80.89 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Alumis Total Liabilities?

Alumis's Total Liabilities for the quarter that ended in Dec. 2024 was $80.89 Mil.

Alumis's quarterly Total Liabilities declined from Jun. 2024 ($703.93 Mil) to Sep. 2024 ($64.17 Mil) but then increased from Sep. 2024 ($64.17 Mil) to Dec. 2024 ($80.89 Mil).

Alumis's annual Total Liabilities increased from Dec. 2022 ($303.41 Mil) to Dec. 2023 ($428.87 Mil) but then declined from Dec. 2023 ($428.87 Mil) to Dec. 2024 ($80.89 Mil).


Alumis Total Liabilities Historical Data

The historical data trend for Alumis's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alumis Total Liabilities Chart

Alumis Annual Data
Trend Dec22 Dec23 Dec24
Total Liabilities
303.41 428.87 80.89

Alumis Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Liabilities Get a 7-Day Free Trial Premium Member Only 428.87 563.30 703.93 64.17 80.89

Alumis Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Alumis's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=50.91+(29.165+0.814
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=80.89

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=340.992-260.103
=80.89

Alumis's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=50.91+(29.165+0.814
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=80.89

Total Liabilities=Total Assets (Q: Dec. 2024 )-Total Equity (Q: Dec. 2024 )
=340.992-260.103
=80.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alumis Total Liabilities Related Terms

Thank you for viewing the detailed overview of Alumis's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Alumis Business Description

Traded in Other Exchanges
N/A
Address
280 East Grand Avenue, South San Francisco, CA, USA, 94080
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.